ArticleEuropean stroke journal2026
Long-term risk of major adverse cardiovascular events after carotid endarterectomy-a 9-year prospective cohort study of the Athero-Express biobank.
Article in European stroke journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCarotid endarterectomy (CEA) is performed to lower the long-term risk of stroke in patients with carotid stenosis. Data evaluating long-term outcomes after CEA are scarce, but crucial for accurately determining long-term benefits. We aimed to estimate the long-term risk of major adverse cardiovascular and cerebrovascular events (MACE) after CEA. PATIENTS AND
methodsA data linkage study was performed using patients from the Athero-Express biobank study who underwent CEA in two Dutch tertiary referral hospitals between 2002 and 2020. Data were linked to the Cause of Death Register, Population Register from Statistics Netherlands and the Hospital Discharge Register. The primary outcome was the occurrence of MACE at any time during follow-up and in the postprocedural (beyond 30 days) period.
resultsCEA was performed in 2123 unique patients; linkage was possible for 1876. Median age was 70 years, 70% was male, and 87% had a symptomatic stenosis. MACE occurred in 455 patients (24.3%) during 9.2 years median follow-up. Five and 10-year cumulative incidence of MACE was 14.3% and 26.4%, respectively. Vascular death was the predominant contributor to MACE with 246 events (54.1%). Older age, current smoking, lower estimated glomerular filtration rate, diabetes mellitus and coronary artery disease (CAD) were associated with an increased risk of MACE. Preoperative antiplatelet use was associated with decreased risk of MACE. Patients with ischaemic stroke as qualifying event were at higher risk of MACE (P = .018). The incidence rate of MACE did not change over time (P = .9). DISCUSSION: Patients remain at high risk of MACE after CEA, especially of vascular death and in older patients, current smokers and patients with diabetes or CAD.
conclusionThese findings underscore the need to enhance cardiovascular preventive strategies following CEA, in order to optimise long-term benefit.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.